Gilead Sciences (NASDAQ:GILD) updated its FY 2020
After-Hours earnings guidance on Thursday. The company provided earnings per share guidance of 6.25-7.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.71. The company issued revenue guidance of $23-25 billion, compared to the consensus revenue estimate of $23.44 billion.Gilead Sciences also updated its FY20 guidance to $6.25-7.65 EPS.

Gilead Sciences stock opened at $69.53 on Friday. The company has a fifty day simple moving average of $75.47 and a 200-day simple moving average of $73.57. The company has a quick ratio of 2.92, a current ratio of 3.04 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $90.73 billion, a price-to-earnings ratio of -289.70, a PEG ratio of 2.43 and a beta of 0.70. Gilead Sciences has a 52-week low of $60.89 and a 52-week high of $85.97.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.46). The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 32.17%. On average, research analysts anticipate that Gilead Sciences will post 6.61 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.91%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.

A number of equities analysts have weighed in on the company. Royal Bank of Canada lowered their price objective on Gilead Sciences from $89.00 to $87.00 and set an outperform rating on the stock in a research note on Friday. Credit Suisse Group lowered their price target on shares of Gilead Sciences from $75.00 to $73.00 and set a neutral rating on the stock in a research report on Friday. Cowen restated a buy rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Monday, April 13th. Piper Sandler reduced their target price on shares of Gilead Sciences from $90.00 to $85.00 and set an overweight rating on the stock in a research note on Friday. Finally, Mizuho reissued a buy rating and issued a $81.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 13th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $79.63.

In other news, EVP Brett A. Pletcher sold 13,210 shares of Gilead Sciences stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the completion of the sale, the executive vice president now directly owns 27,204 shares of the company’s stock, valued at approximately $2,155,372.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Diane E. Wilfong sold 12,264 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $80.09, for a total value of $982,223.76. Following the completion of the transaction, the chief accounting officer now directly owns 23,685 shares in the company, valued at approximately $1,896,931.65. The disclosure for this sale can be found here. Insiders sold 28,079 shares of company stock valued at $2,240,630 in the last quarter. 0.13% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: How is a Moving Average Calculated?

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.